Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hikaru Takamine

Effects of SGLT2 Inhibition on eGFR and Glomerular and Tubular Damage Markers in Japanese Patients With Type 2 Diabetes

Journal of Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2018English

Related publications

Associations of Urinary, Glomerular, and Tubular Markers With the Development of Diabetic Kidney Disease in Type 2 Diabetes Patients

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2017English

Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients

Mediators of Inflammation
ImmunologyCell Biology
2018English

Effects of Synbiotics on Inflammatory Markers in Patients With Type 2 Diabetes Mellitus

Global journal of health science
Medicine
2015English

Serological Markers of Enterocyte Damage and Apoptosis in Patients With Celiac Disease, Autoimmune Diabetes Mellitus and Diabetes Mellitus Type 2

Physiological Research
MedicinePhysiology
2015English

Effect of Irbesartan Treatment on Plasma and Urinary Markers of Protein Damage in Patients With Type 2 Diabetes and Microalbuminuria

Amino Acids
Organic ChemistryBiochemistryClinical Biochemistry
2011English

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment

Clinical Pharmacology in Drug Development
PharmacologyPharmaceutical Science
2018English

Kidney Biomarkers and Decline in eGFR in Patients With Type 2 Diabetes

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2018English

Effects of Chamomile Tea on Inflammatory Markers and Insulin Resistance in Patients With Type 2 Diabetes Mellitus

Trends in General Practice
2018English

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy